| Sep 10 |
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
|
| Aug 30 |
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 16 |
Purple Biotech GAAP EPADS of -$0.09
|
| Aug 16 |
Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights
|
| Jul 25 |
Purple Biotech gets extension to regain compliance with Nasdaq
|
| Jul 25 |
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
|
| Jul 10 |
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
|
| Jul 2 |
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
|
| Jul 1 |
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
|
| Jun 27 |
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
|
